1stOncology™: Cancer Intelligence Service – Page 6590 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Poseida Therapeutics to Present at the ESMO Immuno-Oncology 2022 Annual Congress

On November 3, 2022 Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, reported the acceptance of two poster presentations at the European Society for Medical Oncology Immuno-Oncology (ESMO I-O) 2022 Annual Congress, taking place in Geneva, Switzerland and online from December 7-9, 2022 (Press release, Poseida Therapeutics, NOV 3, 2022, View Source [SID1234623063]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Details of the presentations are as follows. The full abstracts will be made available on the ESMO (Free ESMO Whitepaper) website on December 1, 2022 at 12:05 AM CET.

About P-MUC1C-ALLO1
P-MUC1C-ALLO1 is an allogeneic CAR-T product candidate in Phase 1 development for multiple solid tumor indications. Poseida believes P-MUC1C-ALLO1 has the potential to treat a wide range of solid tumors derived from epithelial cells, such as breast, colorectal, lung, ovarian, pancreatic and renal carcinomas, as well as other cancers expressing a cancer-specific form of the Mucin 1 protein, or MUC1-C. P-MUC1C-ALLO1 is designed to be fully allogeneic, with genetic edits to eliminate or reduce both host-vs-graft and graft-vs-host alloreactivity. Poseida has demonstrated the elimination of tumor cells to undetectable levels in preclinical models of both breast and ovarian cancer. Additional information about the Phase 1 study is available at www.clinicaltrials.gov using identifier: NCT05239143.

About P-BCMA-ALLO1
P-BCMA-ALLO1 is an allogeneic CAR-T product candidate, partnered with Roche, targeting B-cell maturation antigen (BCMA) for the treatment of relapsed/refractory multiple myeloma in Phase 1 development. In vitro and in vivo P-BCMA-ALLO1 preclinical studies, showed effective, targeted cancer cell killing and cytokine secretion, with similar or superior anti-tumor efficacy compared to an autologous CAR-T therapy. Additional information about the Phase 1 study is available at www.clinicaltrials.gov using identifier: NCT04960579.

Acepodia to Present Preclinical Data on its Gamma Delta T cell Therapy Candidate, ACE1831, at 2022 SITC Annual Meeting

On November 3, 2022 Acepodia, a clinical-stage biotechnology company developing first-in-class cell therapies with its unique antibody-cell conjugation (ACC) technology to address gaps in cancer care, reported the upcoming poster presentation of new preclinical data for ACE1831, a gamma delta 2 T cell therapy being developed as a treatment for non-Hodgkin’s lymphoma (Press release, Acepodia, NOV 3, 2022, View Source [SID1234623062]). The company will present this data at the 37th annual meeting of the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper), being held in Boston, MA, from November 8 to 12, 2022.

The poster presentation will showcase data demonstrating that ACE1831 is able to target cancer cells, overcome tumor defenses, and deliver a potent, cancer-killing cellular payload.

Details on the presentation and session information are provided below:

Presentation details

The poster presentation will be accessible in person and virtually. All accepted abstracts will be published in a Supplement to the Journal for ImmunoTherapy of Cancer (JITC).

"Acepodia’s unique Antibody-Cell Conjugation (ACC) technology platform is inherited from the lab of Dr. Carolyn Bertozzi, 2022 Nobel Prize laureate in Chemistry, where she pioneers work in the development of biorthogonal chemistry and moves click chemistry into living organisms. Antibody-Cell Conjugation technology uses this live-cell compatible chemistry to link any tumor-targeting antibody to the surface of human immune cells. This powerful, new approach to cell therapy development has the potential to enhance the ability of γδ2 T cells to recognize and engage the tumor by unlocking multiple receptor signaling pathways. This could potentially allow ACC-γδ2 T therapies to overcome the challenges that have prevented cell therapies from effectively targeting solid tumors," said Sonny Hsiao, Ph.D., chief executive officer and co-founder of Acepodia. "We plan to continue developing novel off-the-shelf cell therapy that leverage our unique ACC technology platform, which can be applied to a variety of immune effector cells, and we look forward to advancing our ACE1831 into phase 1 clinical study in 2022."

About Gamma-Delta T Cells
Acepodia’s gamma delta T cell program harnesses the unique properties of gamma delta T cells to develop a new class of off-the-shelf cell therapies for the treatment of cancer. Gamma delta T cells have characteristics of both the innate and adaptive immune systems that make them an ideal chassis for the development of cell therapies. This cell type can recognize and attack cancerous cells as well as coordinate a broad antitumor immune response by recruiting other immune factors and cells to the site of disease. Gamma delta T cells have also been shown to preferentially traffic to distinct tissues and could be ideally suited for more targeted treatment of certain types of cancers.

Pathios Therapeutics to Present Preclinical Data Highlighting Potential of GPR65 Inhibition as a Powerful Anti-Tumor Immunotherapy Strategy at SITC 2022

On November 3, 2022 Pathios Therapeutics Limited ("Pathios"), a biotech company focused on the development of first-in-class therapies for cancer, reported that new preclinical data highlighting the therapeutic potential of the company’s novel GPR65 inhibition platform will be the focus of a poster presentation at the upcoming 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) (SITC 2022) (Press release, Pathios Therapeutics, NOV 3, 2022, View Source [SID1234623061]). Presented results will showcase the company’s unique approach to "macrophage conditioning" with novel GPR65 inhibitors as a means to reversing the immunosuppression that results from an acidic tumor microenvironment, and, in turn, driving anti-tumor activity. SITC (Free SITC Whitepaper) 2022 is being held November 8-12, 2022, in Boston, Massachusetts.

Details of the company’s presentation at SITC (Free SITC Whitepaper) 2022 are as follows:

About Acidity in the Tumor Microenvironment
The acidic tumor microenvironment, inherent to many cancers, causes a profound immunosuppression of infiltrating immune cells. This environment disarms the anti-cancer immune response and negates the effectiveness of current immunotherapies. This is particularly evident in tumor associated macrophages (TAM), where acidity is sensed by the cell-surface receptor GPR65, leading to the widespread suppression of a host of pro-inflammatory mediators and anti-tumorigenic genes, as well as the upregulation of several tissue repair genes and angiogenic factors.

ImmunoGenesis to Present Pre-Clinical Data from Lead Program at Society for Immunotherapy of Cancer Conference

On November 3, 2022 ImmunoGenesis, a clinical-stage biotechnology company developing science-driven immune therapies, reported that two poster presentations on its lead development program, IMGS-001, will be presented at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 37th Annual Meeting (SITC 2022), November 8-12, 2022, in Boston, MA (Press release, ImmunoGenesis, NOV 3, 2022, View Source [SID1234623060]). The posters will be available on the ImmunoGenesis website following the conference.

About IMGS-001, a PD-L1/PD-L2 Dual-Specific Inhibitor
ImmunoGenesis’ lead program is IMGS-001, a PD-L1/PD-L2 dual-specific inhibitor with an engineered cytotoxic effector function. As the first molecule to target PD-L2 in addition to PD-L1, IMGS-001 has the potential to shut down the entire PD-1 pathway, potentially providing superior blockade compared to other PD-1 or PD-L1 inhibitors. The built-in engineered effector function allows IMGS-001 to kill immunosuppressive cells that express PD-L1 and/or PD-L2. Preclinical data showed that IMGS-001 offered five times the response rate in cold tumors than currently available immunotherapies. Additionally, IMGS-001 can provide a foundation for add-on therapies.

Regulus Therapeutics Announces Timing for Third Quarter 2022 Financial Results Webcast and Conference Call

On November 3, 2022 Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), reported that it will report its third quarter 2022 financial results on Thursday, November 10, 2022, after the U.S. financial markets close (Press release, Regulus, NOV 3, 2022, View Source [SID1234623059]).

In connection with the earnings release, Regulus’ management team will host a live conference call and webcast on the same day at 5:00 PM ET, to discuss the Company’s financial results and provide a corporate update. To access the call, please dial (866) 652-5200 (domestic) or (412) 317-6060 and use the conference ID 10171026. To access the telephone replay of the call, dial (877) 344-7529 (domestic) or (412) 317-0088 and refer to the entry replay code 5033234 The webcast and telephone replay will be archived on the Company’s website at www.regulusrx.com following the call.